Floatz logo

sl-279252

Cervical Squamous Cell Carcinoma

Shattuck Labs, Inc.Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Cervical Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2BB
Hycamtin
National Cancer Institute (NCI)
Phase 2B
PEGFILGRASTIM
National Cancer Institute (NCI)
Phase 2B
Veliparib
National Cancer Institute (NCI)
Phase 2B
FILGRASTIM
National Cancer Institute (NCI)
Phase 2B

View all 32 →

Same molecule, other indications

sl-279252 is also rated in:

head and neck squamous cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
anal squamous cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
skin squamous cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →